SecSonar.com

Altimmune, Inc. (ALT)

Altimmune, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Altimmune, Inc. (ALT) is a Biotechnology company based in US with a market capitalization of $270.9M. Revenue grew 105.0% year-over-year and free cash flow was negative at -$67.5M. This page tracks ALT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 59 employees · IPO May 26, 2017

Valuation

Valuation & price

$2.85 · as of May 17, 2026 · -53.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.20

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.18$4.38$2.59Jul 25Dec 25Jul 26Jul 7, 25$4.43Jul 9, 25$4.74Jul 11, 25$4.14Jul 15, 25$4.18Jul 17, 25$4.05Jul 21, 25$4.05Jul 23, 25$4.29Jul 25, 25$4.08Jul 29, 25$3.83Jul 31, 25$3.69Aug 4, 25$3.58Aug 6, 25$3.60Aug 11, 25$3.38Aug 13, 25$3.74Aug 15, 25$3.63Aug 19, 25$3.62Aug 21, 25$3.53Aug 25, 25$3.39Aug 27, 25$3.67Aug 29, 25$3.83Sep 3, 25$3.68Sep 5, 25$3.78Sep 9, 25$3.78Sep 11, 25$3.69Sep 16, 25$3.63Sep 18, 25$3.87Sep 22, 25$3.96Sep 24, 25$3.92Sep 26, 25$4.00Sep 30, 25$3.77Oct 2, 25$3.93Oct 6, 25$4.01Oct 8, 25$3.93Oct 10, 25$3.92Oct 14, 25$3.97Oct 16, 25$3.89Oct 21, 25$4.04Oct 23, 25$3.96Oct 27, 25$4.14Oct 29, 25$4.00Oct 31, 25$4.05Nov 4, 25$3.76Nov 6, 25$3.94Nov 10, 25$4.26Nov 12, 25$4.23Nov 14, 25$4.17Nov 18, 25$4.65Nov 20, 25$4.47Nov 25, 25$5.14Nov 28, 25$5.26Dec 2, 25$4.76Dec 4, 25$5.31Dec 8, 25$5.61Dec 10, 25$5.43Dec 12, 25$5.27Dec 16, 25$5.03Dec 18, 25$5.05Dec 22, 25$4.14Dec 24, 25$3.98Dec 29, 25$3.68Jan 2, 26$3.51Jan 6, 26$3.96Jan 8, 26$4.08Jan 12, 26$4.05Jan 14, 26$4.18Jan 16, 26$4.24Jan 21, 26$4.62Jan 23, 26$5.50Jan 27, 26$6.18Jan 29, 26$5.10Feb 2, 26$5.55Feb 4, 26$5.13Feb 9, 26$4.69Feb 11, 26$4.63Feb 13, 26$4.53Feb 18, 26$4.46Feb 20, 26$4.38Feb 24, 26$4.57Feb 26, 26$4.46Mar 2, 26$4.16Mar 4, 26$4.27Mar 6, 26$3.54Mar 10, 26$3.86Mar 12, 26$3.60Mar 17, 26$3.53Mar 19, 26$3.42Mar 23, 26$3.44Mar 25, 26$3.31Mar 27, 26$3.02Mar 31, 26$3.08Apr 2, 26$3.34Apr 7, 26$3.38Apr 9, 26$3.38Apr 13, 26$3.23Apr 15, 26$3.40Apr 17, 26$3.50Apr 22, 26$3.47Apr 24, 26$2.85Apr 28, 26$2.74Apr 30, 26$2.60May 4, 26$3.02May 6, 26$3.26May 8, 26$3.09May 12, 26$3.08May 14, 26$2.92May 18, 26$2.80May 20, 26$2.82May 22, 26$2.90May 28, 26$3.07Jun 1, 26$3.01Jun 3, 26$2.87Jun 5, 26$2.71Jun 9, 26$2.66Jun 11, 26$2.59Jun 15, 26$2.64Jun 17, 26$2.64Jun 22, 26$2.93Jun 24, 26$2.95Jun 26, 26$2.82Jul 2, 26$3.16
$2.5952-week range$6.18
Loading valuation history…

Fundamentals

Key fundamentals

$270.9M

Market cap

105.0%

Revenue growth (YoY)

100.0%

Gross margin

-$67.5M

Free cash flow (USD)

-$237.8M

Net debt

Net cash position

24.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$5.2MFY 2017$41.5KFY 2018$10.3MFY 2019$5.8MFY 2020$8.2MFY 2021$4.4MFY 2022$-68.0KFY 2023$426.0KFY 2024$20.0KFY 2025$41.0K
$5.2M$41K

Free cash flow by year

2016 → 2025

FY 2016$201.5MFY 2017$-20.4MFY 2018$-10.4MFY 2019$-9.6MFY 2020$-34.6MFY 2021$-90.5MFY 2022$-62.7MFY 2023$-75.9MFY 2024$-79.8MFY 2025$-67.5M
$201.5M-$67.5M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventHeadquarters RelocationJun 16, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • 8-K eventStock OfferingApr 24, 2026Filing
  • 8-K eventAuthorized Shares IncreaseApr 16, 2026Filing
  • Insider buyInsider Buy $31KGILL JOHN · Director · $31.3KApr 6, 2026Filing
  • Insider buyInsider Buy $47KDurso Jerome Benedict · Director, President and CEO · $47.1KApr 1, 2026Filing
  • Insider buyInsider Buy $31KWEAVER GREGORY L · Chief Financial Officer · $31.5KApr 1, 2026Filing

Questions

Frequently asked questions

What is Altimmune, Inc.'s market cap?

Altimmune, Inc. (ALT) has a market capitalization of $270.9M.

What is ALT's P/E ratio?

A meaningful P/E ratio is not available for ALT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ALT's price-to-book (P/B) ratio?

ALT trades at 1.20 times book value per share.

Are insiders buying ALT stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Altimmune, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

MGNX

MacroGenics, Inc.

$270.5M

TRDA

Entrada Therapeutics, Inc.

$272.5M

AKBA

Akebia Therapeutics, Inc.

$280.3M

ACIU

AC Immune S.A.

$281.4M

IVA

Inventiva S.A.

$259.9M

CDXS

Codexis, Inc.

$258.1M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.